Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing incidence of retinal disorder
3.2.1.2 Increasing prevalence of diabetes and hypertension
3.2.1.3 Advancements in treatment methods
3.2.1.4 Growing R&D investment and activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects of the treatment
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porters anlaysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Condition Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Branch retinal vein occlusion (BRVO)
5.3 Central retinal vein occlusion (CRVO)
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Anti-VEGF therapy
6.3 Corticosteroids
6.4 Laser therapy
6.5 Other treatment types
Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generics
Chapter 8 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Ophthalmic clinics
8.4 Ambulatory surgical centers (ASCs)
8.5 Academic and research institutes
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Allergan, Inc.
10.2 Aerie Pharmaceuticals Inc.
10.3 Bayer AG
10.4 Biocon Biologics Ltd
10.5 Chugai Pharmaceutical Co., Ltd.
10.6 Coherus BioSciences, Inc.
10.7 EyePoint Pharmaceuticals Inc.
10.8 Genentech Inc. (F. Hoffmann-La Roche Ltd.)
10.9 Novartis AG
10.10 Regeneron Pharmaceuticals Inc
10.11 Samsung Bioepis Co., Ltd.
